Navigation Links
David Nagel Joins Align Technology Board of Directors
Date:7/15/2009

SANTA CLARA, Calif., July 15 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN) today announced that it has appointed David C. Nagel, Ph.D. to its board of directors. Dr. Nagel will serve as a member of the compensation committee and as chair of the technology committee. Dr. Nagel also serves on the board of directors of Leapfrog Enterprises Inc., Openwave Systems, Inc., and Tessera Technologies, Inc.

"Dr. Nagel's extensive technical knowledge and senior leadership experience in consumer technology companies with strong global brands such as Apple, AT&T and Palm is a tremendous asset for Align," said Thomas M. Prescott, president and CEO of Align Technology, Inc. "Dr. Nagel is a great addition to our board of directors and we are honored to have him chair our technology committee. We look forward to his contributions as we continue to create the next generation of Invisalign and drive adoption worldwide."

Dr. Nagel was most recently president and CEO of PalmSource, now known as ACCESS Systems Americas, Inc., a subsidiary of ACCESS which develops the Palm OS PDA operating system. Nagel also served as a member of the Palm board of directors. Prior to joining Palm, Nagel was the chief technology officer at AT&T and president of AT&T Labs. Earlier in his career, Nagel was senior vice president at Apple Computer where he led the worldwide research and development group responsible for Mac OS software, Macintosh hardware, imaging and other peripheral products development. Before joining Apple, Nagel was head of NASA human factors research at NASA's Ames Research Center. Nagel holds B.S. and M.S. degrees in engineering and a Ph.D. in perception and mathematical psychology, all from UCLA.

About Align Technology, Inc.

Align Technology des
'/>"/>

SOURCE Align Technology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
3. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
4. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
5. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
6. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
7. David Grimes, FHI physician, inducted into Institute of Medicine
8. David Kahal Joins AXA Equitable as National Sales Manager
9. Leading Authority on Health Benefits, David Hom, Joins Board of Directors of Healthcare Technology Innovator, NavigatorMD, Inc.
10. Tree named in honor of Virginia Tech chemist David G.I. Kingston
11. David Luci Joins MacroChem as General Counsel and Vice President Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...t Washington University School of Medicine in St. ...pic worms to survive in a low-oxygen, or hypoxic, ...e implications for conditions such as stroke, hear...the Jan. 30 issue of the journal Science . , "In...
... Today, Jiffy Lube® service centers in S...entral Coast of California, the Spokane and Tri-Ci...nounce their participation in the second year of t... the nation,s number one killer of women and men, ...
... illness in cattle months before symptoms appear, ...thDay News) -- A simple, inexpensive DNA blood tes...cattle months before they show any clinical signs ...brain samples from dead animals. The ability to te...
... (BRONX, NY) Men who develop prostate cancer face...f they carry a so-called breast cancer gene mutati... Medicine of Yeshiva University report in today,s ... The study, involving 979 men with prostate cancer...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) c...D filing with the Securities and Exchange Commissi...filiated funds announcing their intent to nominate... this action. , , Amylin,s Corporate Governance C...
...nly used to improve physical function, decrease sy...ow back or neck pain. Numerous randomized trials a...s practice, and studies suggest that individually ...on, including who is prescribing it, who is gettin...
Other Medicine News:Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 2Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 2Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 3Health News:Jiffy Lube Service Centers Kick-off Year Two Of Maintenance Partners For Life Campaign To Benefit American Heart Association 4Health News:Blood Test for 'Mad Cow' Disease May Be Near 2Health News:Gene mutations increase risk for aggressive prostate cancer 2Health News:Gene mutations increase risk for aggressive prostate cancer 3Health News:Exercise underutilized for chronic back and neck pain 2Health News:Exercise underutilized for chronic back and neck pain 3
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Thomson Reuters Partners With Sagient Research 13050 1Thomson Reuters Partners With Sagient Research 13050 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 1NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 2NEA Portfolio Companies Selected as Zero2IPO Venture 50 and China Entrepreneur Rising Stars Honorees 51801 3Number of Underweight Kids in U S Continues to Shrink 51798 1
...KERB Demonstrates Activity in Combination with Oth...ss A Range of Breast Cancer Settings, - First Pha...R2 and VEGF, pathways with two oral, small molecul...ib) demonstrates activity in first-line HER2 (ErbB...er(1) - Phase II results combining TYKERB and AVA...
...ICAGO, May 31 Millennium Pharmaceuticals, The Tak...tion of results from three,clinical trials of VELC...complete remission(1) (CR) rates in patients with ...f the best predictors of long-term survival. These... at the American Society,of Clinical Oncology (ASC...
Other Medicine Technology:New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 2New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 3New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 4New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 6New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 7New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 8New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 9New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 10Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
Bechert Nucleus Rotator
Lambert Membrane Hook-Pick - Right
Olk Angled Retinal Pick - 150 Degree
Sweeney Manipulator Cracker
Medicine Products: